KRAS is the most commonly mutated gene in cancer, responsible for mutations in 17% to 25% of all cases. This gene plays a ...

According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline ...

Hereditary changes in genes are often the cause of rare diseases. For example, disease-causing gene variants (PVs) in the ...

A mutation in the KRAS gene can lead to uncontrollable cell growth and the development of cancer. Having this mutation can significantly influence the treatment and outlook of people with colon ...

Researchers at the University of Dundee’s Centre for Targeted Protein Degradation (CeTPD) and Boehringer Ingelheim have ...

New research from the University of Dundee shows potential breakthrough for hard to treat cancers. Experts from the ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim ...

Experts have developed a breakthrough small-molecule drug, a 'protein degrader'. This molecule, called ACBI3, could potentially lead to new therapies independent of KRAS mutation type, improving ...

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

For example, disease-causing gene variants (PVs) in the HRAS gene cause Costello syndrome and PVs in the KRAS gene cause Noonan syndrome and cardio-facio-cutaneous ... A dog's pain medication ...

I highlight potential of Biomea Fusion's diabetes drug amid competition, advises caution with stock due to risks. Read more ...